FDA approves second drug in new class against diabetes

The second of a new class of anti-diabetes drugs has won marketing approval in the US. The FDA has given the green light to the SGLT-2 inhibitor dapagliflozin (Farxiga).

The drug was co-developed by Bristol-Myers Squibb and AstraZeneca but AZ has now taken full control of the product – see ‘Bristol-Myers Squibb to sell stake in diabetes alliance to AstraZeneca’ (https://pharmaphorum.com/news/bristol-myers-squibb-to-sell-stake-in-diabetes-alliance-to-astrazeneca).

“On December 19, 2013 AstraZeneca and Bristol-Myers Squibb announced an agreement under which AstraZeneca will acquire the entirety of Bristol-Myers Squibb’s interests in the companies’ diabetes alliance to consolidate worldwide ownership of the diabetes business within AstraZeneca.”

Bristol-Myers Squibb statement.

 

pharmaphorum-google-plus-page

Related news:

FDA approves AZ’s Farxiga (dapagliflozin) (Medical Marketing & Media magazine).

FDA approves dapagliflozin (Farxiga) for type 2 diabetes treatment (Medscape).

FDA clears BMS/AZ’s dapagliflozin at second attempt (PMLiVE)

Reference link:

Astrazeneca and Bristol-Myers Aquibb announce US FDA approval of Farxiga (dapagliflozin) (BMS press release).

Don't miss your daily pharmaphorum news.
SUBSCRIBE free here.